A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)

Trial Profile

A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Ticagrelor (Primary) ; Clopidogrel
  • Indications Cardiovascular disorders; Embolism and thrombosis; Myocardial infarction; Peripheral arterial disorders; Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms EUCLID
  • Sponsors AstraZeneca
  • Most Recent Events

    • 13 Nov 2016 Results comparing superiority of Ticagrelor versus Clopidogrel published in the New England Journal of Medicine .
    • 13 Nov 2016 Results of pre-specified subgroup (n=7875) analysis focusing on patients entering the study based on the prior lower extremity revascularization criterion published in the Circulation
    • 25 Oct 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top